Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01227889
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Condition: Cancer
Interventions: Drug: GSK2118436;   Drug: Dacarbazine (DTIC)

Study has passed its completion date and status has not been verified in more than two years.